Strides Arcolab soars as its arm receives US FDA approval for Zoledronic Acid

06 Mar 2013 Evaluate

Strides Arcolab is currently trading at Rs. 900.30, up by 22.45 points or 2.56% from its previous closing of Rs. 877.85 on the BSE.

The scrip opened at Rs. 884.45 and has touched a high and low of Rs. 905.45 and Rs. 884.45 respectively. So far 119902 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1224.90 on 05-Dec-2012 and a 52 week low of Rs. 542.35 on 06-Mar-2012.

Last one week high and low of the scrip stood at Rs. 1125.00 and Rs. 816.00 respectively. The current market cap of the company is Rs. 5311.74 crore.

The promoters holding in the company stood at 27.51% while Institutions and Non-Institutions held 49.31% and 23.18% respectively.

Agila Specialties, a wholly owned subsidiary of Strides Arcolab has received ANDA approval for Zoledronic Acid Injection 4 mg (base)/ 5ml packaged in Single dose vials. Zoledronic Acid is used to treat high blood calcium levels (hypercalcemia) that may occur with cancer.

According to IMS data, the US market for Zoledronic Acid 5ML is approximately $520 million. The product is expected to be launched shortly.

Strides Arcolab is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.

Strides Pharma Scien Share Price

942.00 -8.50 (-0.89%)
05-Jul-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1568.85
Dr. Reddys Lab 6536.00
Cipla 1509.40
Zydus Lifesciences 1162.40
Lupin 1769.40
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.